Drugs that melt cancer cells start selling in the market

A drug that can "melt" cells that have been treated in Australia, reported ABC News on January 10.

Venetoclax drug will be marketed under the name Venclexta, which has been certified by the Australian Drug Administration (TGA) for patients with chronic lymphocytic leukemia . The drug is also certified for use in the US since the end of 2016, which will help patients without standard treatment or any other therapy.

Andrew Roberts, a hematology professor working at Royal Melbourne Hospital.

Andrew Roberts, a hematology professor working at Royal Melbourne Hospital, said the drug also binds to a number of certified treatments to treat other types of blood cancers . "Research is under way to show that this drug is very suitable to fight other types of cancer, so this start is a major turning point," said Robert.

Venetoclax works by blocking the activity of BCL-2 protein that allows cancer cells to grow, a solution that researchers worldwide have been working on for more than 30 years.

Dr. David Huang, drug development scientist from the Walter and Eliza Hall Institute of Medical Research won the 2016 Eureka Medical Inventory Science Award.

Doug Hilton, director of the Walter and Eliza Hall Medical Research Institute, said certification is important for patients with limited treatment options."As a poisoned arrow, Venetoclax drugs aim directly at the BCL-2 protein center , " said Hilton for ABC News. "Australians with chronic lymphocytic leukemia can now benefit from a drug like Venetoclax," he added.